Table 1 Baseline characteristics of the included trials
Study | Publication year | Type | Study cohort | Study totol size | Randomization | Follow up (month) | ||
|---|---|---|---|---|---|---|---|---|
Mehdi Akrami et al. [7] | 2021 | RCT | ACS | 249 | Colchicine (n = 120) | VS | Placebo (n = 129) | 6 |
LoDoCo2 [9] | 2020 | RCT | CCS | 5522 | Colchicine (n = 2762) | VS | Placebo (n = 2760) | 28.6 |
CIRT [22] | 2018 | RCT | MI and MS OR T2MD | 4786 | Methotrexa (n = 2391) | VS | Placebo (n = 2395) | 27.6 |
COLCOT [8] | 2019 | RCT | MI | 4745 | Colchicine (n = 2366) | VS | placebo (n = 237) | 22.6 |
CANTOS [11] | 2017 | RCT | MI | 10,061 | Canakinumab (n = 6717) | VS | placebo (n = 3344) | 48 |
STABILITY [15] | 2014 | RCT | CCS | 15,828 | Darapladib (n = 7924) | VS | placebo (n = 7904) | 44.4 |
SOLID-TIMI [16] | 2014 | RCT | ACS | 13,026 | Darapladib (n = 6504) | VS | placebo (n = 6522) | 30 |
VISTA-16 [14] | 2013 | RCT | ACS | 5145 | Varespladib (n = 2572) | VS | placebo (n = 2673) | 6 |
COPS [20] | 2020 | RCT | ACS | 795 | Colchicine (n = 396) | VS | placebo (n = 399) | 12 |
FRANCIS [21] | 2010 | RCT | ACS | 625 | Varespladib (n = 313) | VS | placebo (n = 311) | 6 |